Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)

NCT07840326 is registered in ClinicalTrials.gov with Sundance Biosciences, Inc. as lead sponsor.

NCT NCT07840326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07840326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
Lead sponsor
Sundance Biosciences, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
October 31, 2026
Completion date
July 31, 2027
Enrollment
20 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-active secondary progressive multiple sclerosis, non-active spms, primary progressive ms, primary progressive multiple sclerosis, primary progressive multiple sclerosis (ppms), secondary progressive ms, secondary progressive ms (spms), secondary progressive multiple sclerosis (spms), secondary progressive multiple sclerosis with inflammatory disease activity